Literature DB >> 23073266

Treat-to-target: rationale and strategies.

Josef S Smolen1.   

Abstract

Treatment to a target level of a variable known to be associated with bad disease outcome is a concept that has been applied for many years in several specialties. In rheumatology this has not been the case, primarily because of the complexity of measures assessing disease activity of RA and insufficient knowledge of optimal strategies. Meanhwile, however, our insights into the devastating role of active disease have expanded. In parallel, the use of composite measures of disease activity to control patients tightly and adapt therapy accordingly has provided the evidence that treating RA to a target value of low disease activity or remission conveys significant benefit. The background of the treat-to-target concept and future aspects are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073266

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  16 in total

1.  Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study.

Authors:  Herwig Pieringer; Rudolf Puchner; Erich Pohanka; Kathrin Danninger
Journal:  Clin Rheumatol       Date:  2015-03-26       Impact factor: 2.980

Review 2.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

3.  Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérrez; A Escudero-Contreras; J R Del Prado; E Collantes-Estévez; P Font
Journal:  Rheumatol Int       Date:  2016-10-24       Impact factor: 2.631

Review 4.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

5.  Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; P Font; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérez; A Escudero-Contreras; M A Casado; J R Del Prado; E Collantes-Estévez
Journal:  Rheumatol Int       Date:  2016-02       Impact factor: 2.631

Review 6.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

7.  Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.

Authors:  Tatsuya Koike
Journal:  J Orthop Sci       Date:  2015-09-25       Impact factor: 1.601

8.  Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.

Authors:  Vibeke Strand; Paul Miller; Setareh A Williams; Katherine Saunders; Shannon Grant; Joel Kremer
Journal:  Rheumatol Ther       Date:  2017-08-22

9.  Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice.

Authors:  Peter C Taylor; Rieke Alten; Juan J Gomez Reino; Roberto Caporali; Philippe Bertin; Emma Sullivan; Robert Wood; James Piercy; Radu Vasilescu; Dean Spurden; Jose Alvir; Miriam Tarallo
Journal:  Patient Prefer Adherence       Date:  2018-10-04       Impact factor: 2.711

10.  Interface Management between General Practitioners and Rheumatologists-Results of a Survey Defining a Concept for Future Joint Recommendations.

Authors:  Rudolf Puchner; Michael Edlinger; Erich Mur; Gabriele Eberl; Manfred Herold; Peter Kufner; Antonia Puchner; Stephan E Puchner; Kurt Redlich; Alois Alkin; Klaus Machold
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.